LLY vs DGX
By Alex · Tickerpine
Eli Lilly and Company vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DGX |
|---|---|---|
| Price | $1,443.50 | $259.60 |
| Market cap | $1.29T | $28.56B |
| P/E ratio | 46.9 | 25.9 |
| ROE | 86.02% | 15.32% |
| Profit margin | 31.90% | 9.54% |
| Revenue growth | 38.60% | 10.00% |
| Dividend yield | 0.48% | 1.33% |
| Beta | 0.39 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DGX in plain English
- LLY is the bigger company — about 45.0× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.9 vs 46.9).
- LLY earns a higher return on equity (86% vs 15%).
- LLY is growing revenue faster (39% vs 10%).
- DGX has the higher dividend yield (1.33% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.